The Multifaceted Role of Striatin-interacting Protein 2 (STRIP2) in Disease Pathogenesis and Cancer Progression.

Abstract

Striatin-interacting protein 2 (STRIP2), encoded by the STRIP2 gene, plays a critical role in various biological processes. It is an integral part of the striatin-interacting phosphatase and kinase (STRIPAK) complex and is involved in cell growth, proliferation, migration, and differentiation. In this review, we explored the multifaceted functions of STRIP2 across different cancers, including non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, prostate cancer, and others. We searched the PubMed database for studies investigating STRIP2 in tumors or pathological processes. Our search yielded 30 studies. After meticulous screening, only 14 studies were included in this review. Based on our results, STRIP2 is overexpressed and amplified in multiple cancer types, including NSCLC, breast cancer, colorectal cancer, and prostate cancer, and is associated with poor prognosis. In NSCLC, it promotes tumor progression through mechanisms involving mRNA stabilization, Akt/mTOR pathway, epithelial-mesenchymal transition (EMT), and immune regulation. In breast and colorectal cancers, elevated STRIP2 levels correlate with reduced overall survival. In prostate cancer, STRIP2 contributes to cell migration and cytoskeletal organization. Furthermore, interaction of STRIP2 with immune checkpoint genes suggests its role in tumor immune evasion, offering therapeutic potential for targeting the tumor microenvironment. We conclude that STRIP2 acts as an oncogene in various tumors and is associated with a poor prognosis. It is involved in critical oncogenic pathways including proliferation, EMT, and immune regulation, highlighting its potential as a therapeutic target. This review supports the importance of investigating the diagnostic, prognostic, and therapeutic role of STRIP2 in various cancers, particularly NSCLC.